ciprofloxacin has been researched along with hmr 3647 in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Jansen, WT; Milatovic, D; Verel, A; Verhoef, J | 1 |
| Beceiro, A; Bou, G; Canle, D; Fernández, A; Lasa, I; Latasa, C; Mallo, S; Molina, F; Pérez, A; Pérez, S; Poza, M; Tomás, Mdel M; Villanueva, R | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Calvet, L; Devine, R; Dubreuil, L; Jean-Pierre, H; Jumas-Bilak, E; Marchandin, H; Mercier, G; Morio, F | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Benton, BM; Debabov, DV; Difuntorum, S; Krause, KM; Renelli, M; Wu, TX | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Arhin, FF; Draghi, DC; Moeck, G; Parr, TR; Pillar, CM; Sahm, DF | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Gunell, M; Hakanen, AJ; Huovinen, P; Jalava, J; Kotilainen, P; Siitonen, A | 1 |
| Biedenbach, DJ; Castanheira, M; Jones, RN | 1 |
| Biedenbach, DJ; Hammerschlag, MR; Jones, RN; Kohlhoff, SA; Roblin, PM | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Fajdetić, A; Mutak, S; Pavlović, D | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Mutak, S; Pavlović, D | 2 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kimmins, S; Mutak, S; Pavlović, D | 1 |
| Cushman, M; Fan, BZ; Han, X; Kong, FS; Li, YX; Liang, JH; Lv, W; Ma, CX; Tian, JC | 1 |
| Cushman, M; Fan, BZ; Guo, SY; Kong, FS; Li, XM; Li, YX; Liang, JH; Lv, W; Zhang, J | 1 |
| Cooper, DL; He, H; Lovett, ST; Shy, A; Sun, S; Wang, J; Wu, D; Xu, B; Xu, J; Zhan, W | 1 |
| Aldrich, C; Brody, S; Cushman, M; Fan, BZ; Hiasa, H; Liang, JH; Lv, W; Yang, ZY | 1 |
| Cushman, M; Ding, J; Li, Y; Liang, JH; Liu, LY; Liu, XP; Lv, W; Xue, F; Zhang, JR; Zhang, JZ; Zhao, F | 1 |
1 review(s) available for ciprofloxacin and hmr 3647
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
26 other study(ies) available for ciprofloxacin and hmr 3647
| Article | Year |
|---|---|
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Europe; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes; Vancomycin Resistance; Viridans Streptococci | 2007 |
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
Topics: Bacterial Proteins; Base Sequence; beta-Lactamases; Carrier Proteins; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Genes, MDR; Genetic Vectors; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Porins | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Antimicrobial susceptibilities and clinical sources of Dialister species.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Species Specificity; Veillonellaceae | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
In vitro activity of telavancin against resistant gram-positive bacteria.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus; Streptococcus | 2008 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus faecium; Glycopeptides; Gram-Positive Bacteria; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
In vitro activity of azithromycin against nontyphoidal Salmonella enterica.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Drug Resistance, Bacterial; Finland; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Salmonella enterica; Salmonella Infections | 2010 |
Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Minocycline; Neisseria meningitidis; Penicillins; Rifampin; Sulfamethoxazole; Triazoles; Trimethoprim | 2010 |
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
Topics: Anti-Bacterial Agents; Chlamydia trachomatis; Fusidic Acid; Neisseria gonorrhoeae | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple; Erythromycin; Haemophilus influenzae; Ketolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Quinolones; Staphylococcus aureus; Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.
Topics: | 2011 |
Synthesis and antibacterial evaluation of novel 4″-glycyl linked quinolyl-azithromycins with potent activity against macrolide-resistant pathogens.
Topics: Anti-Bacterial Agents; Azithromycin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Haemophilus influenzae; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2016 |
Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
Topics: Animals; Anti-Bacterial Agents; Biological Availability; Drug Resistance, Bacterial; Erythromycin; Humans; Macrolides; Structure-Activity Relationship | 2017 |
Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Bacterial; Ketolides; Microbial Sensitivity Tests; Molecular Structure; Oximes; Quinolones; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2019 |
Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH.
Topics: Anti-Bacterial Agents; Bacteria; Clarithromycin; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2019 |
Structure-Activity Relationship of Peptide-Conjugated Chloramphenicol for Inhibiting
Topics: Anti-Bacterial Agents; Chloramphenicol; Escherichia coli; Microbial Sensitivity Tests; Peptides; Structure-Activity Relationship | 2019 |
Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides.
Topics: Anti-Bacterial Agents; Azithromycin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Escherichia coli; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2020 |
Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides.
Topics: Anti-Bacterial Agents; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Quinolones; Structure-Activity Relationship | 2022 |